Pliant Therapeutics, Inc. (PLRX): Long-Term Debt
$0
As of 2025-12-31
$0
As of 2026-06-30
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $0 | -100.0% | 2026-03-11, Balance as of period end |
| 2024-12-31 | $30.21M | +200.5% | 2026-03-11, Balance as of period end |
| 2023-12-31 | $10.05M | +1.3% | 2025-03-03, Balance as of period end |
| 2022-12-31 | $9.93M | n/a | 2024-02-27, Balance as of period end |
| 2021-12-31 | $0 | n/a | 2023-03-09, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Pliant Therapeutics, Inc. (PLRX) | 2025-12-31 | $0 | -100.0% |
| Abbott Laboratories (ABT) | 2025-12-31 | $12.93B | -8.5% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $44.83B | -9.3% |
| Eli Lilly & Co (LLY) | 2024-12-31 | $29.47B | +54.3% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $41.44B | +27.9% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $27.13M | -6.3% |
| Sarepta Therapeutics, Inc. (SRPT) | 2025-12-31 | $828.97M | n/a |
| Ionis Pharmaceuticals Inc (IONS) | 2025-12-31 | $1.81B | +44.6% |
| Bausch Health Companies Inc. (BHC) | 2025-12-31 | $20.82B | -3.7% |
Compare PLRX, ABT, BMY, LLY side by side · Screen every company in Pharmaceutical Preparations ↗